Patents by Inventor Michael Koeris

Michael Koeris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bacteriophages expressing antimicrobial peptides and uses thereof
    Patent number: 10676721
    Abstract: The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: June 9, 2020
    Assignees: Trustees of Boston University, Massachusetts Institute of Technology
    Inventors: James J. Collins, Michael Koeris, Timothy Kuan-Ta Lu, Gregory Stephanopoulos, Christopher Jongsoo Yoon
  • BACTERIOPHAGES EXPRESSING ANTIMICROBIAL PEPTIDES AND USES THEREOF
    Publication number: 20150050717
    Abstract: The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.
    Type: Application
    Filed: September 2, 2011
    Publication date: February 19, 2015
    Applicants: Massachusetts Institute of Technology, Trustees of Boston University
    Inventors: James J. Collins, Michael Koeris, Timothy Kuan-Ta Lu, Gregory Stephanopoulos, Christopher Yoon